FDA aims to fast track two Merck drugs with high sales potential, Reuters says

The FDA is preparing to accelerate reviews of two experimental Merck (MRK) drugs with multibillion-dollar sales potential, Patrick Wingrove and Dan Levine of Reuters reported, citing internal documents. Merck’s cholesterol treatment enlicitide decanoate and its cancer therapy sacituzumab tirumotecan have been selected for the FDA’s Commissioner’s National Priority Voucher program, a designation that could make them the seventeenth and eighteenth drugs included in the initiative, according to the documents.